Trial ID: | L3181 |
Source ID: | NCT03320031
|
Associated Drug: |
Linagliptin
|
Title: |
A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy
|
Acronym: |
|
Status: |
UNKNOWN
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Type 2 Diabetes Mellitus|Peritoneal Dialysis
|
Interventions: |
DRUG: Linagliptin|DRUG: Humalog Mix 75/25
|
Outcome Measures: |
Primary: glucose variability, The change from baseline to week 12 in glucose variability indicated by MAGE., 12 weeks | Secondary: HbA1c, Changes in HbA1c between two groups, 12 weeks|FPG, Changes in FPG between two groups, 12 weeks|insulin dosage, Changes in FPG at the end between two groups, 12 weeks|body weight, Changes in body weight at the end between two groups, 12 weeks|hypoglycemia, Frequency of hypoglycemia at the end in each gropu, 12 weeks
|
Sponsor/Collaborators: |
Sponsor: Yanbing Li
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE4
|
Enrollment: |
232
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2017-06-03
|
Completion Date: |
2019-12
|
Results First Posted: |
|
Last Update Posted: |
2017-10-24
|
Locations: |
endocrinology department of the first affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
|
URL: |
https://clinicaltrials.gov/show/NCT03320031
|